Pembrolizumab in CRC: What did we learn from the KEYNOTE-177 and the KEYNOTE-651 trials? - report from ASCO2022

from Medical Digest & Congress Report · host Medical Congress News

Professor Richard D. Kim presented a data about the long term follow-up of the KEYNOTE-651 study at the recent ASCO 2022 congress. We asked him about the new informations and also about the KEYNOTE-177 trial. Video: https://congressreport.eu/scientific-contents/interview:pembrolizumab-crc-what-did-we-learn-keynote-177-and-keynote-651-trials

Episode metadata supplied by the publisher feed · Published Jun 15, 2022

Embed this episode

Attribution link and audio player

Ready to play

Pembrolizumab in CRC: What did we learn from the KEYNOTE-177 and the KEYNOTE-651 trials? - report from ASCO2022

0:00 6:32

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 6 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on June 15, 2022.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!